Elvitegravir Description

Elvitegravir is a animal immunodeficiency virus type 1 (HIV-1) integrase fiber alteration inhibitor (INSTI) used for the analysis of HIV-1 infection in antiretroviral treatment-experienced adults. Because integrase is all-important for viral replication, inhibition prevents the affiliation of HIV-1 DNA into the host genome and thereby blocks the accumulation of the HIV-1 provirus and consistent advancement of the viral infection. Although accessible as a individual dosage tablet, elvitegravir have to be used in aggregate with an HIV protease inhibitor coadministered with ritonavir and addition antiretroviral drug.

It was developed by the biologic aggregation Gilead Sciences, which accountant EVG from Japan Tobacco in March 2008. The biologic acquired approval by the U.S. Food and Biologic Administration on August 27, 2012 for use in developed patients starting HIV analysis for the aboriginal time as allotment of the anchored dosage aggregate known as Stribild. On September 24, 2014 the FDA accustomed Elvitegravir (tradename Vitekta) as a individual bolus formulation.

Elvitegravir is an HIV-1 integrase fiber alteration inhibitor (INSTI). Integrase is an HIV-1 encoded agitator that is appropriate for viral replication. Inhibition of integrase prevents the affiliation of HIV-1 DNA into host genomic DNA, blocking the accumulation of the HIV-1 provirus and advancement of the viral infection. Elvitegravir does not arrest animal topoisomerases I or II.